HOME >> BIOLOGY >> NEWS
Drug combo effective in advanced breast cancer

A pair of studies at UCLA's Jonsson Cancer Center taking laboratory science to the patient bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.

The results of the studies, the first done on cell lines in the laboratory and the second translated into more than 120 patients in two Phase II clinical trials, appear Tuesday (May 18) in the peer-reviewed Journal of the National Cancer Institute.

In an accompanying editorial, Dr. George W. Sledge, Jr., co-director of the Breast Cancer Program at the Indiana University School of Medicine, called the studies "an impressive example of translational research at its best."

"Designing a sequential series of experiments, both laboratory and clinical, that lead intentionally to proof-of-concept adjuvant (Phase III) trials is all too rare," Sledge states in the editorial. "But, as (UCLA researchers) remind us, it is not impossible."

Jonsson Cancer Center researchers first tested drug combinations in the laboratory with the goal of translating their results into patients with HER2/neu amplification, a genetic alternation found in 20 to 25 percent of patients that leads to an aggressive form of breast cancer.

Lead by researchers Dr. Dennis Slamon and Dr. Mark Pegram, the laboratory studies analyzed Herceptin for interaction with nine chemotherapy drugs commonly used to treat breast cancer. Researchers found that the chemotherapy agents Taxotere, Navelbine, Cyclophosphamide and the platinum salts Cisplatin and Carboplatin increased the activity of Herceptin in lab models with HER2/neu amplification. In other words, Herceptin and the chemotherapy agents each made the other more effective, a synergistic effect. The laboratory studies pointed researchers to the optimum chemotherapy combination, which
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
18-May-2004


Page: 1 2 3

Related biology news :

1. Avastin-Tarceva combo provides one-two punch against lung cancer
2. Toxin combo common in fish appears capable of impairing motor skills
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. Rum and coke combo far worse on the brain, study shows
5. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
6. Endurance exercise found to be equally effective as diuretics in improving cardiac health
7. Purdue yeast makes ethanol from agricultural waste more effectively
8. Scientists learn how adjuvant makes vaccines effective
9. Super-effective jumping gene created
10. Data show investigational antibiotic safe, effective in preventing travelers diarrhea
11. Mexican farmers effectively cultivate phenotypic diversity in maize

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/11/2019)... ... June 10, 2019 , ... Improved Pharma LLC announces ... 2019 issue of AAPS PharmSciTech. The article was published online on April 29th, 2019. ... Pharma, along with Xiaoming Sean Chen of Purdue University. , The article is the ...
(Date:6/6/2019)... ... June 05, 2019 , ... Pelican ... new network station and service center in Mexico City, Mexico. Mexico is the ... — with more than $1.75 billion in pharmaceutical exports since 2015. The Mexico ...
(Date:6/4/2019)... Tenn. (PRWEB) , ... June 04, 2019 , ... ... contract manufacturing of orthopedic medical devices, today announced Q1-19 revenues of $31M, up ... industry combined with successful roll-out of strategic investments & operational excellence initiatives worldwide. ...
Breaking Biology News(10 mins):
(Date:6/6/2019)... ... 05, 2019 , ... WCCT Global, Inc ., a full-service early phase ... they will be receiving 3 awards at the 2019 CRO Leadership Awards, to be ... the categories of overall Quality and Compatibility (Access to desired markets, cultural fit, timely ...
(Date:5/31/2019)... ... May 30, 2019 , ... A ... an efficient delivery system for the sustained release of human placental stem cell ... system was able to deliver CM into the injured kidney, where it helped ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak ... instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited ... website aims to improve LDA’s ability to communicate directly with the marketplace; serving ...
(Date:5/4/2019)... N.J. (PRWEB) , ... May 03, 2019 , ... ... announces the release of the Diopsys® ffERG/Photopic Negative Response vision test, ... glaucoma. , By 2050, it is estimated that 6.3 million Americans will have ...
Breaking Biology Technology:
Cached News: